Kura Oncology and Kyowa Kirin Announce FDA Acceptance of New Drug Application for Ziftomenib in Relapsed or Refractory AML with NPM1 Mutation

Kura Oncology and Kyowa Kirin announced the FDA's acceptance of the New Drug Application for ziftomenib, a menin inhibitor, for relapsed or refractory AML with an NPM1 mutation, granting Priority Review with a PDUFA target action date of November 30, 2025. The NDA is based on positive Phase 2 KOMET-001 trial results, potentially making ziftomenib the first approved therapy of its kind for this AML subset, which currently has limited treatment options. Despite promising efficacy and safety data, the companies acknowledge the lengthy review process and inherent risks in drug commercialization.

Analysis

The U.S. Food and Drug Administration's (FDA) acceptance of Kura Oncology's (KURA) and Kyowa Kirin's (4151) New Drug Application (NDA) for ziftomenib represents a significant regulatory advancement for the treatment of adult patients with relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). The application has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025. This development is notable as ziftomenib has the potential to be the first approved menin inhibitor for this specific AML patient population, which currently faces a dire prognosis with limited therapeutic options and a median overall survival of approximately 7.8 months in the 2nd line setting. The NDA is underpinned by positive pivotal data from the Phase 2 KOMET-001 trial, which successfully met its primary endpoint related to complete remission rates and demonstrated that ziftomenib was well-tolerated, with only 3% of discontinuations attributed to the drug. Ziftomenib's therapeutic promise is further underscored by its prior receipt of Breakthrough Therapy, Fast Track, and Orphan Drug Designations from the FDA. Despite these positive developments, the PDUFA date points to a considerable review timeline of nearly 18 months. Institutional investor activity in KURA stock presents a mixed picture: BVF Inc/IL added 5,186,660 shares (+202.0%) and Suvretta Capital Management added 2,362,811 shares (+46.5%) in Q1 2025, while Deerfield Management Company L.P. (Series C) divested its entire 5,411,571 share position in Q4 2024, and Avoro Capital Advisors LLC sold all its 2,250,000 shares in Q1 2025. Furthermore, KURA insiders have exclusively sold stock in the past six months, with 17 sales and zero purchases recorded, which warrants consideration alongside the positive clinical and regulatory news.

Key Decisions for Investors

• Investors should recognize the FDA's NDA acceptance for ziftomenib as a key de-risking event and a step towards addressing a significant unmet medical need in NPM1-mutant AML, while also factoring in the extended PDUFA timeline to November 30, 2025, for potential market entry.
• For Kura Oncology (KURA), the pattern of 17 insider sales without any purchases over the last six months, coupled with substantial Q4 2024 and Q1 2025 divestitures by some large hedge funds, should be weighed against the positive ziftomenib news and new institutional investments when assessing risk.
• Monitor forthcoming full data presentations from the KOMET-001 trial at the 2025 ASCO Annual Meeting and EHA Congress for deeper insights into ziftomenib's clinical profile, which will be crucial for re-evaluating the long-term commercial prospects leading up to the PDUFA date.